Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662243 · ClinicalTrials.gov registry record
Treatment for Reading and Writing Deficits Following Acquired Brain Injury
A clinical trial, sponsored by Quality Living.
- Completed
- Registry status
- 2
- Enrollment target
NCT03662243 is a clinical trial that has completed, run by Quality Living. The registered enrollment target is 2 participants.
The verdict
NCT03662243 has completed, sponsored by Quality Living.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Many people with acquired brain injuries have deficits in reading decoding, reading comprehension, and written expression. Alexia is a phenomenon in which a person who previously could read has trouble doing so after having sustained a brain injury; likewise, agraphia is an acquired writing problem affecting one or more aspects of written communication. Alexia and agraphia sometimes co-occur with one another and/or with other language challenges, but they can also occur as isolated phenomena. Methods to treat alexia and agraphia often focus on single intervention techniques that address aspects of reading or writing in isolation-such as matching written and spoken letters or letter sounds, performing choral reading, tracing letters, etc. Existing research suggests that the effectiveness of these techniques is limited. However, when used in combination, such techniques may promote improved reading and written communication skills. As such, the purpose of this research is to determine the extent to which a multicomponent intervention program improves the reading and writing capabilities of people with acquired alexia and/or agraphia.
Interventions
- BEHAVIORAL Multicomponent reading and writing treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2020-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03662243
The ClinicalTrials.gov registry entry for NCT03662243 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quality Living, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multicomponent reading and writing treatment is the first listed.
NCT03662243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03662243 about?
NCT03662243 is a clinical study titled "Treatment for Reading and Writing Deficits Following Acquired Brain Injury". Many people with acquired brain injuries have deficits in reading decoding, reading comprehension, and written expression. Alexia is a phenomenon in which a person who previously could read has trouble doing so after having sustained a brain injury; likewise, agraphia is an acquired writing problem ...
What is the current status of trial NCT03662243?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2018-08-30. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03662243?
The interventions under investigation include: Multicomponent reading and writing treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT03662243?
This trial is sponsored by Quality Living, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.